Endocyte Inc fka ECYT

[InvestingSmart1123]

True, yet Aria bottom out at $2.15. Very risky play when you look into ECYT "stopped a late-stage study of an ovarian-cancer treatment because results fell short of its goals". With the ovarian cancer Phase 3 halt and now "Endocyte said it would refocus on proprietary drugs", current price level will be under attack in the coming days. Again this is jmo. The once promising ovarian cancer Phase 3 trial was what makes ECYT price even at $30 would be under priced, but with that halt ECYT is neck under water like the rest of the fail/trial halt biotech.